Barclays PLC Increases Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK)

Barclays PLC lifted its holdings in Outlook Therapeutics, Inc. (NASDAQ:OTLK) by 677.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,943 shares of the company’s stock after purchasing an additional 18,249 shares during the period. Barclays PLC owned about 0.09% of Outlook Therapeutics worth $111,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of OTLK. Great Point Partners LLC increased its stake in shares of Outlook Therapeutics by 15.0% in the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock valued at $12,557,000 after purchasing an additional 221,510 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in Outlook Therapeutics during the 2nd quarter worth approximately $232,000. AQR Capital Management LLC purchased a new stake in Outlook Therapeutics during the 2nd quarter worth approximately $75,000. Susquehanna Fundamental Investments LLC purchased a new stake in Outlook Therapeutics during the 2nd quarter worth approximately $303,000. Finally, Christensen King & Associates Investment Services Inc. purchased a new stake in Outlook Therapeutics during the 3rd quarter worth approximately $55,000. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. BTIG Research cut their price objective on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 29th. Chardan Capital restated a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. Finally, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Outlook Therapeutics in a report on Friday, November 29th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.73.

Outlook Therapeutics Stock Performance

OTLK opened at $2.18 on Thursday. Outlook Therapeutics, Inc. has a one year low of $0.87 and a one year high of $12.85. The stock has a market capitalization of $54.30 million, a PE ratio of -0.20 and a beta of 0.53. The business’s 50 day moving average price is $3.33 and its 200 day moving average price is $5.61.

Outlook Therapeutics (NASDAQ:OTLK) last released its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.06. As a group, equities research analysts forecast that Outlook Therapeutics, Inc. will post -3.84 earnings per share for the current fiscal year.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.